The FDA has announced draft guidance for pulse oximeter manufacturers, requiring more diverse clinical studies to improve accuracy for patients of color. Recommendations include enrolling at least 150 participants from various skin tones and evaluating pigmentation through scientific methods. This move addresses longstanding concerns about device inaccuracies, particularly for those with darker skin. The guidance follows alarming studies indicating that oximeters may overestimate oxygen levels in Black, Asian, and Hispanic patients, leading to delayed treatment and increased health risks. Public comments on the draft will be accepted for 60 days before finalization.